Factors Associated with 18F-Fluorodeoxyglucose Uptake in T1 and T2 Invasive Ductal Carcinoma of the Breast
Purpose The objective of this study was to investigate the relationship between diversity of 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake of primary tumor in positron emission tomography (PET) and various clinicopathologic factors in breast cancer of same pathologic T1, T2 stage. Methods A total of 25...
Gespeichert in:
Veröffentlicht in: | Nuclear medicine and molecular imaging 2016, 50(3), , pp.240-245 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
The objective of this study was to investigate the relationship between diversity of
18
F-fluorodeoxyglucose (
18
F-FDG) uptake of primary tumor in positron emission tomography (PET) and various clinicopathologic factors in breast cancer of same pathologic T1, T2 stage.
Methods
A total of 258 patients with invasive ductal breast cancer were enrolled in this study. All patients underwent
18
F-FDG PET-CT before surgery. Patients were divided into two groups according to tumor size based on the pathologic T stage, and maximum standardized uptake value (SUVmax) of 2.5, respectively.
Results
On the univariate analysis, estrogen receptor (ER), tumor size, lymphovascular invasion, p53, pathologic N status (pN) and Nottingham tumor grade (NG) were associated with high SUVmax in T1 and T2 breast cancer. On the multivariate logistic regression, tumor size and NG remained significant variables dividing high and low SUVmax. In the T1 group, ER, p53 and NG were significantly associated with high SUVmax on the univariate analysis. In this group, p53 and NG remained significant variables for dividing high and low SUVmax on the multivariate logistic regression. In the T2 group, only NG was associated with high SUVmax on the univariate analysis.
Conclusions
NG showed an association with
18
F-FDG uptake in both T1 and T2 breast cancer independently; however, p53 in T1 breast cancer. |
---|---|
ISSN: | 1869-3474 1869-3482 |
DOI: | 10.1007/s13139-016-0409-x |